Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin

Diabetes, Obesity and Metabolism

Volumn 20, Issue 5, 2018, Pages 1321-1326

  Polidori, David ^a   Iijima, Hiroaki ^b   Goda, Maki ^b   Maruyama, Nobuko ^b   Inagaki, Nobuya ^c   Crawford, Peter A ^d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

canagliflozin; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; CANAGLIFLOZIN; FATTY ACID; GLUCOSE; INSULIN; KETONE; ACETOACETIC ACID DERIVATIVE; KETONE BODY;

ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE DURATION; DRUG EFFECT; DRUG INHIBITION; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE (PEOPLE); KETOGENESIS; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADMINISTRATION AND DOSAGE; ANALYSIS; BIOLOGICAL VARIATION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETIC KETOACIDOSIS; DOSE RESPONSE; FEMALE; FOLLOW UP; HYPERGLYCEMIA; HYPOGLYCEMIA; JAPAN; PATHOPHYSIOLOGY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SEXUAL CHARACTERISTICS; UPREGULATION;

3-HYDROXYBUTYRIC ACID; ACETOACETATES; BIOLOGICAL VARIATION, POPULATION; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; JAPAN; KETONE BODIES; MALE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; UP-REGULATION;

EID: 85042042148     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13224     Document Type: Article

References (19)

1. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304(8):H1060-H1076.
2. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25(2):262-284.
3. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133(8):698-705.
4. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38(12):2344-2353.
5. Inagaki N, Kondo K, Yoshinari T, Kuki H. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Investig. 2015;6(2):210-218.
6. Yabe D, Iwasaki M, Kuwata H, et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab. 2017;19(5):739-743.
7. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032-2038.
8. US Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed December 13, 2017.
9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
10. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
11. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115-1122.
12. Al Jobori H, Daniele G, Adams J, et al. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab. 2017;19(6):809-813.
13. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190-1195.
14. Okamoto A, Yokokawa H, Sanada H, Naito T. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R D. 2016;16(3):255-261.
15. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680-1686.
16. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411-419.
17. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study. Circulation. 2017;136(3):249-259.
18. Abdul-Ghani M, Del Prato S, Chilton R, Defronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39(5):717-725.
19. Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016;15(1):123.